Phase II Study of MK-3475 as Maintenance Therapy in Extensive Stage Small Cell Lung Cancer (SCLC) Patients

Trial Profile

Phase II Study of MK-3475 as Maintenance Therapy in Extensive Stage Small Cell Lung Cancer (SCLC) Patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results assessing the efficacy and safety of pembrolizumab in extensive stage small cell lung cancer patients, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 26 Mar 2017 Planned End Date changed from 1 Jan 2017 to 31 Jul 2017.
    • 26 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 31 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top